Atsena Therapeutics

Executive Summary

Atsena Therapeutics is a clinical-stage gene therapy company dedicated to treating inherited retinal diseases (IRDs), with a lead program targeting GUCY2D-associated Leber congenital amaurosis type 1 (LCA1), a severe early-onset blindness caused by mutations in the GUCY2D gene. The company leverages a novel subretinal delivery approach designed to improve safety and efficacy compared to conventional methods by directly targeting photoreceptor cells. In preclinical studies, its AAV-based gene therapy demonstrated vision restoration in animal models. Atsena is currently enrolling patients in a Phase 1/2 clinical trial to evaluate the safety and preliminary efficacy of its candidate. With $150 million raised to date, the company is backed by top-tier investors and has a strong intellectual property portfolio. Beyond LCA1, Atsena is expanding its pipeline to address other IRDs, capitalizing on its proprietary delivery platform. The company's strategic focus on monogenic ocular diseases positions it to address significant unmet medical needs, as current treatment options for these conditions are limited. If successful, Atsena's therapies could provide durable vision restoration for patients, representing a paradigm shift in ophthalmology.

Upcoming Catalysts (preview)

• Q3 2026Interim Phase 1/2 Data for LCA1 Gene Therapy60% success
• Q1 2026FDA IND Clearance for Second Pipeline Candidate70% success
• Q2 2026Strategic Partnership or Series C Funding Announcement50% success